Colgate-Palmolive (CL)CEO sold ~$4.28M

~$4.28M

Approx. value · 46K sh @ $93.91

293K

Holds after · shares reported

Traded

Feb 4, 2026

Filed

Feb 6, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jan 30, 2026Company filing · Form 8-K · ResultsReported its results
2. Feb 4, 2026 · this disclosureInsiderCEO sold ~$4.28M of CL shares in the open market

What came next

1. Feb 4, 2026Insider · 2 peopleInsiders: 2 sales (~$11.3M)
2. Feb 5, 2026InsiderOfficer sold ~$1.51M of CL shares in the open market
3. Feb 6, 2026InsiderOfficer sold ~$1.21M of CL shares in the open market
4. Feb 10, 2026InsiderOfficer sold ~$1.98M of CL shares in the open market
5. Feb 11, 2026InsiderOfficer sold ~$3.31M of CL shares in the open market
6. Feb 12, 2026InsiderOfficer sold ~$1.47M of CL shares in the open market
7. Mar 12, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 12, 2026, the Board of Directors (the “Board”) of Colgate-Palmolive Company (“Colgate-Palmolive”) elected Christopher S. Boerner, Ph.D., Board Chair and Chief Executive Officer of Bristol-Myers Squibb Company (“Bristol Myers Squibb”), to the Colgate-Palmolive Board, effective March 15, 2026.”
8. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
9. Apr 8, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“Jennifer M. Daniels, who has served as Chief Legal Officer and Secretary of Colgate-Palmolive Company (the “Company”) since 2014, has communicated to the Company her intention to retire from the Company in 2026.”
10. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
11. Apr 30, 2026Company filing · Form 8-K · Results, RestructuringAnnounced job cuts, closures or a restructuring, and reported its results“As previously disclosed, on July 31, 2025, the Company’s Board of Directors (“Board”) approved a three-year productivity program to drive future growth and support the Company’s 2030 strategy (the “Strategic Growth and Productivity Program”).”
12. May 7, 2026InsiderOfficer sold ~$752K of CL shares in the open market
13. May 15, 2026InsiderOfficer sold ~$203K of CL shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Colgate-Palmolive

For Colgate-Palmolive, OQRO holds 4 insider filings (SEC Form 4 or Form 144), 6 Congress trade reports and 39 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CL page.

Other recent filings by Noel R. Wallace, Chairman, President & CEO

• SEC Form 4 at Colgate-Palmolive (CL)Aug 6, 2026
• SEC Form 4 at Colgate-Palmolive (CL)Aug 6, 2026
• SEC Form 4 at Colgate-Palmolive (CL)Nov 26, 2024

The full history of Noel R. Wallace, Chairman, President & CEO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Colgate-Palmolive

• House Clerk periodic transaction reportSep 25, 2026
• House Clerk periodic transaction reportSep 25, 2026
• House Clerk periodic transaction reportSep 25, 2026
• House Clerk periodic transaction reportSep 1, 2026
• SEC Form 4Aug 26, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its CL page.